KR20140072108A - 경피용 치료학적 시스템 - Google Patents

경피용 치료학적 시스템 Download PDF

Info

Publication number
KR20140072108A
KR20140072108A KR1020147010333A KR20147010333A KR20140072108A KR 20140072108 A KR20140072108 A KR 20140072108A KR 1020147010333 A KR1020147010333 A KR 1020147010333A KR 20147010333 A KR20147010333 A KR 20147010333A KR 20140072108 A KR20140072108 A KR 20140072108A
Authority
KR
South Korea
Prior art keywords
tts
active ingredient
ribastigmine
layer
preferred
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020147010333A
Other languages
English (en)
Korean (ko)
Inventor
폴 엠. 자르지울로
로저 마이클 레인
베아트릭스 플라트
프랑크 테오발트
베티나 발
Original Assignee
노파르티스 아게
에르테에스 로만 테라피-시스테메 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37716856&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20140072108(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노파르티스 아게, 에르테에스 로만 테라피-시스테메 아게 filed Critical 노파르티스 아게
Publication of KR20140072108A publication Critical patent/KR20140072108A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020147010333A 2005-12-01 2006-10-10 경피용 치료학적 시스템 Withdrawn KR20140072108A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74151105P 2005-12-01 2005-12-01
US60/741,511 2005-12-01
PCT/US2006/039557 WO2007064407A1 (en) 2005-12-01 2006-10-10 Transdermal therapeutic system

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020087013112A Division KR20080071581A (ko) 2005-12-01 2006-10-10 경피용 치료학적 시스템

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020177006994A Division KR20170033449A (ko) 2005-12-01 2006-10-10 경피용 치료학적 시스템

Publications (1)

Publication Number Publication Date
KR20140072108A true KR20140072108A (ko) 2014-06-12

Family

ID=37716856

Family Applications (7)

Application Number Title Priority Date Filing Date
KR1020177006994A Ceased KR20170033449A (ko) 2005-12-01 2006-10-10 경피용 치료학적 시스템
KR1020227039266A Ceased KR20220156666A (ko) 2005-12-01 2006-10-10 경피용 치료학적 시스템
KR1020137031255A Ceased KR20130143729A (ko) 2005-12-01 2006-10-10 경피용 치료학적 시스템
KR1020187012945A Ceased KR20180050441A (ko) 2005-12-01 2006-10-10 경피용 치료학적 시스템
KR1020087013112A Ceased KR20080071581A (ko) 2005-12-01 2006-10-10 경피용 치료학적 시스템
KR1020217001087A Ceased KR20210008440A (ko) 2005-12-01 2006-10-10 경피용 치료학적 시스템
KR1020147010333A Withdrawn KR20140072108A (ko) 2005-12-01 2006-10-10 경피용 치료학적 시스템

Family Applications Before (6)

Application Number Title Priority Date Filing Date
KR1020177006994A Ceased KR20170033449A (ko) 2005-12-01 2006-10-10 경피용 치료학적 시스템
KR1020227039266A Ceased KR20220156666A (ko) 2005-12-01 2006-10-10 경피용 치료학적 시스템
KR1020137031255A Ceased KR20130143729A (ko) 2005-12-01 2006-10-10 경피용 치료학적 시스템
KR1020187012945A Ceased KR20180050441A (ko) 2005-12-01 2006-10-10 경피용 치료학적 시스템
KR1020087013112A Ceased KR20080071581A (ko) 2005-12-01 2006-10-10 경피용 치료학적 시스템
KR1020217001087A Ceased KR20210008440A (ko) 2005-12-01 2006-10-10 경피용 치료학적 시스템

Country Status (31)

Country Link
US (3) US20070128263A1 (enExample)
EP (5) EP2286802A1 (enExample)
JP (3) JP2009517468A (enExample)
KR (7) KR20170033449A (enExample)
CN (2) CN102048713A (enExample)
AR (2) AR057152A1 (enExample)
AT (1) AT11185U1 (enExample)
AU (1) AU2006320919B2 (enExample)
BR (2) BRPI0619758A2 (enExample)
CA (1) CA2563110A1 (enExample)
DE (2) DE202006021172U1 (enExample)
DK (5) DK2292219T3 (enExample)
EC (1) ECSP088469A (enExample)
ES (1) ES2414455T3 (enExample)
FI (1) FI10268U1 (enExample)
GT (1) GT200800075A (enExample)
IL (4) IL191311A (enExample)
MA (1) MA30022B1 (enExample)
MY (2) MY151020A (enExample)
NO (1) NO20082753L (enExample)
NZ (1) NZ568273A (enExample)
PH (2) PH12013500771A1 (enExample)
PL (1) PL2292219T4 (enExample)
PT (1) PT2292219E (enExample)
RU (1) RU2450805C2 (enExample)
SG (1) SG2014014989A (enExample)
SI (1) SI2292219T1 (enExample)
TN (1) TNSN08238A1 (enExample)
TW (1) TWI389709B (enExample)
WO (1) WO2007064407A1 (enExample)
ZA (1) ZA200803882B (enExample)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI389709B (zh) * 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
US9248104B2 (en) * 2006-08-17 2016-02-02 Core Tech Solutions, Inc. Transdermal methods and systems for treating Alzheimer's disease
TWI541246B (zh) 2008-12-08 2016-07-11 歐陸斯迪公司 二氫羥戊甲嗎啡
GB0823554D0 (en) 2008-12-24 2009-01-28 Novartis Ag Process for the preparation of optically active compounds using transfer hydrogenation
US20100267302A1 (en) * 2009-04-17 2010-10-21 3M Innovative Properties Company Silicone gel adhesive construction
WO2010129689A1 (en) * 2009-05-05 2010-11-11 Forest Laboratories Holdings Limited Milnacipran formulations
US12186426B2 (en) 2009-10-30 2025-01-07 Ix Biopharma Ltd. Solid dosage form
SG174465A1 (en) 2009-10-30 2011-10-28 Ix Biopharma Pte Ltd Fast dissolving solid dosage form
WO2011073362A1 (en) 2009-12-18 2011-06-23 Novartis Ag Process for the preparation of optically active compounds using pressure hydrogenation
US10076502B2 (en) 2009-12-22 2018-09-18 Luye Pharma Ag Transdermal therapeutic system for administering rivastigmine or derivatives thereof
US8962014B2 (en) 2009-12-22 2015-02-24 Acino Ag Transdermal therapeutic system for administering rivastigmine or derivatives thereof
US20100178307A1 (en) * 2010-01-13 2010-07-15 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
DE102010024105A1 (de) * 2010-06-17 2011-12-22 Grünenthal GmbH Transdermale Verabreichung von Memantin
RU2578971C2 (ru) * 2010-06-17 2016-03-27 Лтс Ломанн Терапи-Системе Аг Трансдермальное введение мемантина
DE102010026903A1 (de) 2010-07-12 2012-01-12 Amw Gmbh Transdermales therapeutisches System mit Avocadoöl oder Palmöl als Hilfsstoff
KR101892764B1 (ko) * 2010-07-21 2018-08-28 쓰리엠 이노베이티브 프로퍼티즈 컴파니 경피 접착제 조성물, 디바이스, 및 방법
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
US20120046383A1 (en) * 2010-08-19 2012-02-23 Terumo Kabushiki Kaisha Silicone rubber composition
CN103429606A (zh) 2010-10-01 2013-12-04 现代治疗公司 设计核酸及其使用方法
ES2545094T3 (es) 2010-12-14 2015-09-08 Acino Ag Sistema terapéutico transdérmico para la administración de un principio activo
KR101788802B1 (ko) * 2010-12-24 2017-10-20 주식회사 삼양바이오팜 리바스티그민을 함유하는 경피흡수제제
KR101054317B1 (ko) * 2011-01-28 2011-08-08 신신제약 주식회사 리바스티그민을 함유하는 경피흡수제제
KR101317158B1 (ko) * 2011-02-18 2013-10-15 조선대학교산학협력단 갈란타민 또는 그의 염을 함유하는 경피흡수제제
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
KR20120130073A (ko) * 2011-05-20 2012-11-28 에스케이케미칼주식회사 리바스티그민 함유 패취
US9585862B2 (en) * 2011-05-20 2017-03-07 Sk Chemicals Co., Ltd. Patch containing rivastigmine
WO2013031992A1 (ja) 2011-08-31 2013-03-07 積水メディカル株式会社 貼付剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
KR20190099538A (ko) 2011-10-03 2019-08-27 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드, 및 핵산, 및 이들의 용도
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP4144378A1 (en) 2011-12-16 2023-03-08 ModernaTX, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
KR101399035B1 (ko) * 2011-12-22 2014-05-28 주식회사 트랜스덤 리바스티그민을 함유하는 경피흡수제제
DE102012000369A1 (de) 2012-01-11 2013-07-11 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System mit Cholinesterase-Hemmer
US8871245B2 (en) 2012-02-28 2014-10-28 Nichiban Co., Ltd. Transdermal patch
WO2013142339A1 (en) 2012-03-23 2013-09-26 Novartis Ag Transdermal therapeutic system and method
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
AU2013243954A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
WO2013150542A2 (en) * 2012-04-05 2013-10-10 Sparsha Pharma International Private Limited A transdermal patch for treatment of dementia or alzheimer type dementia
WO2013187451A1 (ja) 2012-06-12 2013-12-19 株式会社 ケイ・エム トランスダーム 貼付剤
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
WO2014028049A1 (en) * 2012-08-15 2014-02-20 Dow Corning Corporation Multi - layer transdermal drug delivery system
EP2893927A4 (en) * 2012-09-03 2016-03-09 Nipro Patch Co Ltd SKIN PATCH
KR20140038237A (ko) * 2012-09-20 2014-03-28 에스케이케미칼주식회사 리바스티그민의 안정성이 개선된 의약품
US20140083878A1 (en) * 2012-09-21 2014-03-27 Mylan Inc. Transdermal drug delivery device
WO2014051128A1 (ja) * 2012-09-28 2014-04-03 株式会社 ケイ・エム トランスダーム 貼付剤
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
DK2922554T3 (en) 2012-11-26 2022-05-23 Modernatx Inc Terminalt modificeret rna
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
WO2014111790A2 (en) 2013-01-15 2014-07-24 Zydus Technologies Limited Stable transdermal pharmaceutical drug delivery system comprising rivastigmine
RU2560668C2 (ru) * 2013-03-04 2015-08-20 Общество с ограниченной ответственностью Научно-производственное объединение "Клеточные технологии" Трансдермальный седативный фармацевтический гель для лечения психоэмоциальных расстройств
AR095259A1 (es) * 2013-03-15 2015-09-30 Noven Pharma Composiciones y métodos para la administración transdérmica de fármacos de amina terciaria
EP2968248A4 (en) * 2013-03-15 2016-08-31 Nal Pharmaceutical Group Ltd TRANSDERMAL ACTIVE COMPOSITION SYSTEM WITH RIVASTIGMIN
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method
US20160206568A1 (en) 2013-06-12 2016-07-21 KM Transderm Ltd. Adhesive sheet for application to the skin, and percutaneous absorption preparation using same
TWI745577B (zh) * 2013-06-12 2021-11-11 日商Ｋｍ特蘭斯達股份有限公司 經皮吸收製劑
WO2015001012A1 (de) 2013-07-03 2015-01-08 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches system mit elektronischem bauteil
BR112016007255A2 (pt) 2013-10-03 2017-09-12 Moderna Therapeutics Inc polinucleotídeos que codificam receptor de lipoproteína de baixa densidade
KR101831290B1 (ko) 2013-10-07 2018-02-22 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 조성물을 사용하여 주의력 결핍 과잉행동 장애, 불안 및 불면증을 치료하기 위한 방법 및 조성물
KR101891185B1 (ko) 2013-10-07 2018-08-24 테이코쿠 팔마 유에스에이, 인코포레이티드 비진정량의 덱스메데토미딘의 경피 전달을 위한 방법 및 조성물
TWI704933B (zh) 2013-10-07 2020-09-21 美商帝國製藥美國股份有限公司 右美托咪啶經皮輸送裝置及使用其之方法
US20160374956A1 (en) 2013-12-12 2016-12-29 Hisamitsu Pharmaceutical Co., Inc. Multilayer type patch
CN103877063A (zh) * 2014-03-24 2014-06-25 张绪伟 一种重酒石酸卡巴拉汀胶囊及其制备方法
EP3129012A4 (en) 2014-04-08 2017-10-11 Teikoku Pharma USA, Inc. Rivastigmine transdermal compositions and methods of using the same
US10308408B2 (en) 2014-05-15 2019-06-04 Nichiban Co., Ltd. Packaging for adhesive patch containing rivastigmine
CA2948221C (en) 2014-05-20 2022-11-22 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system including an interface mediator
EP3145503A1 (en) 2014-05-20 2017-03-29 LTS Lohmann Therapie-Systeme AG Method for adjusting the release of active agent in a transdermal delivery system
CA2948220C (en) 2014-05-20 2023-06-20 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system containing rotigotine
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
CN204119542U (zh) 2014-09-24 2015-01-21 上海荣威塑胶工业有限公司 一种ptc加热器
CN104523656A (zh) * 2014-11-20 2015-04-22 美吉斯制药（厦门）有限公司 一种卡巴拉汀缓释透皮贴剂及其制备方法
WO2016088898A1 (ja) 2014-12-05 2016-06-09 株式会社 ケイ・エム トランスダーム 皮膚貼付用粘着シートおよびそれを用いた経皮吸収製剤
DE102015107743A1 (de) 2015-05-18 2016-11-24 Bsn Medical Gmbh Silikongelbeschichtete adhäsive Schichtstruktur
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
US9980921B2 (en) * 2016-06-30 2018-05-29 Taho Pharmaceuticals Ltd. Transdermal delivery system containing methylphenidate or its salts and methods thereof
JP6864968B2 (ja) 2016-08-22 2021-04-28 救急薬品工業株式会社 貼付剤
EP3338768B1 (en) 2016-12-20 2019-10-30 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system containing asenapine
KR102614709B1 (ko) 2016-12-20 2023-12-18 에르테에스 로만 테라피-시스테메 아게 아세나핀 및 폴리실록산 또는 폴리이소부틸렌을 함유하는 경피흡수 치료 시스템
KR102033686B1 (ko) * 2017-05-19 2019-10-18 보령제약 주식회사 도네페질을 함유하는 마이크로니들 경피 패치
US11389421B2 (en) 2017-09-05 2022-07-19 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system for the transdermal administration of rivastigmine
WO2019175101A1 (en) * 2018-03-13 2019-09-19 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system comprising a silicone acrylic hybrid polymer
JP2021515791A (ja) * 2018-03-13 2021-06-24 エルテーエス ローマン テラピー−ジステーメ アーゲー シリコーンアクリルハイブリッドポリマーを含む経皮治療システム
JP2021517572A (ja) * 2018-03-13 2021-07-26 エルテーエス ローマン テラピー−ジステーメ アーゲー シリコーンアクリルハイブリッドポリマーを含む経皮治療システム
CN112533594A (zh) * 2018-06-19 2021-03-19 罗曼治疗系统股份公司 含有卡巴拉汀的透皮治疗系统
US12329862B2 (en) 2018-06-20 2025-06-17 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
AU2019291060B2 (en) 2018-06-20 2024-09-05 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
EP3919051A4 (en) 2019-01-31 2022-10-26 Hisamitsu Pharmaceutical Co., Inc. ADHESIVE STAMP
CA3146233A1 (en) * 2019-07-09 2021-01-14 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system comprising an active agent-containing layer comprising a silicone-containing polymer and a skin contact layer comprising a silicone gel adhesive
BR112021023509A2 (pt) * 2019-07-09 2022-01-18 Lts Lohmann Therapie Systeme Ag Sistema terapêutico transdérmico compreendendo uma camada contendo o agente ativo compreendendo um polímero acrílico e uma camada de contato com a pele compreendendo um adesivo de gel de silicone
CN113616625B (zh) * 2021-08-26 2023-05-30 大连科翔科技开发有限公司 一种卡巴拉汀的长效透皮贴剂
WO2024160939A1 (en) * 2023-02-01 2024-08-08 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system for the transdermal administration of huperzine a

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU201906B (en) 1987-03-04 1991-01-28 Sandoz Ag Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them
US5059426A (en) * 1989-03-22 1991-10-22 Cygnus Therapeutic Systems Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
US5252335A (en) * 1989-07-12 1993-10-12 Cygnus Therapeutic Systems Transdermal administration of lisuride
DE4301783C1 (de) * 1993-01-23 1994-02-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil
GB9800526D0 (en) 1998-01-12 1998-03-11 Ciba Geigy Ag Organic compounds
US6316023B1 (en) 1998-01-12 2001-11-13 Novartis Ag TTS containing an antioxidant
DE19918106A1 (de) * 1999-04-22 2000-10-26 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit neutralisierten Acrylathaftklebern
DE19922662C1 (de) * 1999-05-18 2000-12-28 Sanol Arznei Schwarz Gmbh Transdermales therapeutisches System (TTS) Tolterodin enthaltend
CN1240384C (zh) * 1999-11-04 2006-02-08 美国爱科赛尔制药有限公司 石杉碱经皮给药制剂
US20030104041A1 (en) * 1999-12-16 2003-06-05 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
US20020192243A1 (en) * 1999-12-16 2002-12-19 Tsung-Min Hsu Transdermal and topical administration of drugs for the treatment of Alzheimer's disease using basic enhancers
DE10033853A1 (de) * 2000-07-12 2002-01-31 Hexal Ag Transdermales therapeutisches System mit hochdispersem Siliziumdioxid
US20020106402A1 (en) * 2000-12-05 2002-08-08 Hartwig Rod Lawson Crystallization inhibition of drugs in transdermal drug delivery systems and methods of use
DE10103860B4 (de) 2001-01-30 2004-12-23 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System für die Verabreichung carboxylgruppenhaltiger, nichtsteroidaler Antiphlogistika, sowie Verfahren zu seiner Herstellung
EP1423127A1 (en) * 2001-08-30 2004-06-02 Ortho-Mcneil Pharmaceutical, Inc. Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors
DE10159745A1 (de) * 2001-12-05 2003-07-03 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit verbessertem Langzeittragekomfort
AU2003227516B2 (en) * 2002-05-31 2008-03-20 H. Lundbeck A/S A combination of an NMDA-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
AU2003274353B2 (en) * 2002-10-24 2007-04-05 Merz Pharma Gmbh & Co. Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
CN1921844A (zh) 2004-02-19 2007-02-28 诺瓦提斯公司 胆碱酯酶抑制剂治疗血管性抑郁症的用途
TWI389709B (zh) * 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
EP2596889B1 (en) * 2011-11-23 2017-04-26 Sandvik Intellectual Property AB A cutting insert and a milling tool

Also Published As

Publication number Publication date
MA30022B1 (fr) 2008-12-01
SI2292219T1 (sl) 2013-08-30
TW200732001A (en) 2007-09-01
IL191311A (en) 2015-02-26
IL250734A0 (en) 2017-04-30
JP2016104737A (ja) 2016-06-09
KR20170033449A (ko) 2017-03-24
IL234291A (en) 2017-02-28
EP2292219A1 (en) 2011-03-09
BR122013013162A2 (pt) 2015-06-30
PL2292219T3 (pl) 2013-09-30
US20130266633A1 (en) 2013-10-10
KR20220156666A (ko) 2022-11-25
DK201300015Y4 (da) 2016-02-12
WO2007064407A1 (en) 2007-06-07
TNSN08238A1 (en) 2009-10-30
DK201300014U1 (da) 2013-02-08
EP1959937A1 (en) 2008-08-27
DK201300015U1 (en) 2013-02-08
BRPI0619758A2 (pt) 2011-10-18
DK201300059U1 (da) 2013-04-29
DE14163637T1 (de) 2015-06-03
TWI389709B (zh) 2013-03-21
PH12013500771A1 (en) 2016-01-18
CN101312717A (zh) 2008-11-26
EP3235495A1 (en) 2017-10-25
ECSP088469A (es) 2008-07-30
DK201300059U3 (da) 2013-05-13
JP2013177419A (ja) 2013-09-09
IL234364A (en) 2016-06-30
EP2292219B9 (en) 2015-02-18
FI10268U1 (fi) 2013-10-18
NZ568273A (en) 2011-06-30
KR20210008440A (ko) 2021-01-21
JP5938612B2 (ja) 2016-06-22
EP2286802A1 (en) 2011-02-23
DK2292219T3 (da) 2013-06-24
RU2008126459A (ru) 2010-01-20
KR20130143729A (ko) 2013-12-31
EP2292219B1 (en) 2013-06-12
PT2292219E (pt) 2013-06-24
PL2292219T4 (pl) 2014-03-31
CA2563110A1 (en) 2007-06-01
DK201300014U3 (da) 2013-05-13
US20140134230A1 (en) 2014-05-15
PH12013500772B1 (en) 2018-04-20
KR20180050441A (ko) 2018-05-14
AR097045A2 (es) 2016-02-17
AU2006320919B2 (en) 2011-04-28
AU2006320919A1 (en) 2007-06-07
CN102048713A (zh) 2011-05-11
US20070128263A1 (en) 2007-06-07
AR057152A1 (es) 2007-11-21
JP2009517468A (ja) 2009-04-30
SG2014014989A (en) 2014-06-27
DK201600113Y4 (da) 2017-06-09
DE202006021172U1 (de) 2013-05-07
PH12013500772A1 (en) 2016-01-18
ZA200803882B (en) 2009-03-25
NO20082753L (no) 2008-08-19
AT11185U1 (de) 2010-06-15
DK201600113U1 (da) 2017-01-13
MY162986A (en) 2017-07-31
JP6298034B2 (ja) 2018-03-20
ES2414455T3 (es) 2013-07-19
HK1153646A1 (en) 2012-04-05
EP2786748A1 (en) 2014-10-08
KR20080071581A (ko) 2008-08-04
MY151020A (en) 2014-03-31
RU2450805C2 (ru) 2012-05-20
GT200800075A (es) 2010-06-01

Similar Documents

Publication Publication Date Title
KR20140072108A (ko) 경피용 치료학적 시스템
US9248104B2 (en) Transdermal methods and systems for treating Alzheimer's disease
TWI621448B (zh) 里曼提明（ｒｉｖａｓｔｉｇｍｉｎｅ）經皮組成物及使用其之方法
MX2008006956A (es) Sistema terapeutico transdermico
HK1153646B (en) Transdermal therapeutic system for the administration of rivastigmine
HK1151740A (en) Transdermal therapeutic system

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20140417

Application number text: 1020087013112

Filing date: 20080530

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20140714

Patent event code: PE09021S01D

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20170407

WITB Written withdrawal of application